Objectives: To compare the efficacy and safety of the injectable neuromodulator, prabotulinumtoxinA, for the treatment of moderate to severe glabellar lines between millennial (born 1982-2000, n=65) and non-millennial (born ≤1981, n=668) patients who participated in the three single-dose Phase III glabellar line clinical studies. Importantly, both cohorts were similarly matched at baseline in the severity of their glabellar lines at maximum frown, as measured on the 4-point Glabellar Line Scale (GLS: 0=none, 1=mild, 2=moderate, 3=severe).
Introduction: Millennials, as defined by the US Census Bureau, were born between 1982 and 2000. Millennial use of aesthetic products is increasing – particularly of those products that are both minimally invasive and can be used preventatively. At the same time, there is a paucity of published clinical trial data in this population.
Materials / method: Post-hoc analyses were performed on the pooled population of all 733 patients treated with 20U prabotulinumtoxinA in the single-dose studies. At the time that these studies were conducted (Jan-Nov 2015), millennial patients were 21-33 years and non-millennial patients were 33-81 years. One of the main efficacy endpoints was the proportion of responders with a ≥1 point improvement from baseline at maximum frown on the 4-point GLS. Global aesthetic improvement and subject satisfaction were also assessed, and treatment-related adverse events of particular interest were summarized.
Results: The proportion of millennial responders with a ≥1 point improvement from baseline on the GLS at maximum frown was greater than that of non-millennials by 7.7% on average across all visits. Differences were statistically significant on Day 90, with responder rates of 90.2% and 76.1%, respectively (p=0.01). Similar trends were observed for global aesthetic improvement and subject satisfaction. Treatment-related headache was observed in 9.0% of millennials and 9.4% of non-millennials; treatment-related eyelid ptosis was observed in 1.5% of millennials and 1.2% of non-millennials.
Conclusion: As evident in these post-hoc analyses, despite similarities in the severity of glabellar lines at maximum frown at baseline, a single dose of 20U prabotulinumtoxinA administered for the treatment of moderate to severe glabellar lines was consistently more efficacious in millennials than non-millennials. Satisfaction among millennials remained very high throughout the study. The treatment was similarly well-tolerated by both cohorts.
Divulgação de informações
Você recebeu algum patrocínio para sua pesquisa neste tema?
Não
Você recebeu algum tipo de honorário, pagamento ou outra forma de compensação por seu trabalho neste estudo?
Não
Você possui relação financeira com alguma entidade que possa competir com os medicamentos, materiais ou instrumentos abordados no seu estudo?
Não
Você detém ou pediu a registro de patente para algum dos instrumentos, medicamentos ou materiais abordados no seu estudo?
Não
Este trabalho não recebeu nenhum patrocínio direto ou indireto. O mesmo está sob a própria responsabilidade do seu autor.